Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B036 in Advanced Urological and Solid Tumors
NCT07744243Phase 1Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SI-B036 in urological cancer (UC) and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
SI-B036
03
Conditions
urological cancer (UC)solid tumor
Beyond the preview
Go deeper on NCT07744243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07744243.